Clinical Trials
54 trialsRibociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
MITO32
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
OVHM-01
University Health Network, Toronto
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
[18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer
Leiden University Medical Center
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
Ludwig Institute for Cancer Research
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
Cantonal Hospital of St. Gallen
Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
University of Wisconsin, Madison
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer
Shanghai East Hospital
ORION-01
National Cancer Centre, Singapore
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Translational Research in Oncology
Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
Oslo University Hospital
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
First Affiliated Hospital of Harbin Medical University
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Medical University Innsbruck
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Vanderbilt-Ingram Cancer Center
Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer
Wake Forest University Health Sciences
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
The University of Texas Health Science Center at San Antonio
Photoacoustic Imaging of the Ovary
UConn Health
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Yale University
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
University of Iowa
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
Burzynski Research Institute
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Wake Forest University Health Sciences
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
OHSU Knight Cancer Institute
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
OHSU Knight Cancer Institute
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Stanford University
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Rutgers, The State University of New Jersey
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Memorial Sloan Kettering Cancer Center
Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer
UNC Lineberger Comprehensive Cancer Center
Seprafilmâ„¢ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
University of British Columbia
Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Minnesota
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
New Mexico Cancer Research Alliance
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
Fred Hutchinson Cancer Center
ETC
H. Lee Moffitt Cancer Center and Research Institute
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
Northwestern University
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Vanderbilt-Ingram Cancer Center
11C Topotecan PET Imaging
Case Comprehensive Cancer Center